Can a bone marrow stimulant help people with leg artery disease walk farther?

NCT ID NCT03304821

Completed Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 13, 2026 · Updated 4 times

Summary

This study tested whether a drug called GM-CSF can improve symptoms and blood flow in people with peripheral artery disease (PAD), a condition where plaque narrows leg arteries, causing pain and limiting walking. 151 participants received either GM-CSF or a placebo for two 3-week treatment periods. The main goal was to see if GM-CSF increased the distance they could walk in 6 minutes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GM-CSF (also called Sargramostim or Leukine)
What this could lead to: If it works, this could point toward a treatment that improves walking ability and blood flow in people with peripheral artery disease.
What could go wrong: This is a Phase 2 trial with 151 participants, so results are still early. The drug may not show significant benefit over placebo, and side effects like injection site reactions or bone pain are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL ARTERY DISEASE (PAD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis peripheral arterial disease vascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERIPHERAL ARTERY DISEASE (PAD)

Contacts and locations

Locations

Emory University Hospital

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.